Safety
Schizophyllan, classified as a beta-glucan and extracted from the fungus ''Schizophyllum commune'', showed no quantifiable adverse reactions through independent scientific procedures. With its classification as a beta-glucan, schizophyllan is generally recognized as safe (GRAS) by the United States FDA. While no distinction has been made specifically for schizophyllan, schizophyllan and other β-glucans have been orally administered safely in a variety of vertebrate species showing immunomodulation: mice, canines, horses, and humans. More specifically, in 2012, mushroom-derived beta-glucans were deemed GRAS by direct FDA review. A March 2017 further demonstrates the safety of schizophyllan in horses.Processing and efficacy
The ability for schizophyllan to produce a physiological response is directly correlated with the extraction process and subsequent processing the compound endures. This theory also coincides with that of other beta-glucans. High doses of schizophyllan are not the primary determinant of an immunological response. Studies have validated that 10 mg (or less) of a high quality, adequately processed chemically similar beta-glucan is a sufficient dose to elicit a measurable effect on immune cells. In addition, small particle beta-glucans modified to prevent re-aggregation during digestion have the most positive effects on immune potentiation. Ninety percent of horses with active ulceration treated with ta schizophyllan-containing polysaccharide blend showed complete resolution and/or improvement in ulcerative areas, increased appetite, weight gain, and positive behavioral changes.References
External links
* Cancer Research UK